BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis-Reference-Cited by-同舟云学术

BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis

Published:2021-04 Issue:4 Volume:21 Page:267-278.e10
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Punnoose Elizabeth^ORCID,Peale Franklin V.,Szafer-Glusman Edith,Lei Guiyuan^ORCID,Bourgon Richard,Do An D.^ORCID,Kim Eugene,Zhang Liping,Farinha Pedro^ORCID,Gascoyne Randy D.,Munoz F. Javier,Martelli Maurizio,Mottok Anja,Salles Gilles A.^ORCID,Sehn Laurie H.,Seymour John F.^ORCID,Trnĕný Marek,Oestergaard Mikkel Z.,Mundt Kirsten E.,Vitolo Umberto

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference63 articles.

1. Diffuse large B-cell lymphoma;Martelli;Crit Rev Oncol Hematol,2013

2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project;Blood,1997

3. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project;Anderson;Ann Oncol,1998

4. My treatment approach to patients with diffuse large B-cell lymphoma;Armitage;Mayo Clin Proc,2012

5. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand;PLOS ONE;2024-07-22

2. Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma;American Journal of Hematology;2024-05-03

3. Oxymatrine relieves high-fructose/fat-induced obesity via reprogramming the activity of lipid metabolism-related enhancer;Frontiers in Endocrinology;2023-08-04

4. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial;Blood Advances;2023-05-11

5. Clinical Experience with Pro‐Apoptotic Agents;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15